PierPaolo Peruzzi, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glioblastoma | 13 | 2023 | 3346 | 1.780 |
Why?
|
| Glioma | 5 | 2023 | 3318 | 0.920 |
Why?
|
| MicroRNAs | 6 | 2019 | 3715 | 0.920 |
Why?
|
| Brain Neoplasms | 11 | 2023 | 8657 | 0.890 |
Why?
|
| Poliovirus | 1 | 2018 | 108 | 0.650 |
Why?
|
| Comovirus | 1 | 2015 | 5 | 0.570 |
Why?
|
| Genetic Engineering | 2 | 2019 | 946 | 0.530 |
Why?
|
| Neurosurgery | 1 | 2021 | 629 | 0.520 |
Why?
|
| Vestibular Nerve | 1 | 2014 | 101 | 0.500 |
Why?
|
| Oncolytic Virotherapy | 4 | 2023 | 490 | 0.480 |
Why?
|
| Transgenes | 2 | 2019 | 1016 | 0.410 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2019 | 8452 | 0.400 |
Why?
|
| Neuroma, Acoustic | 1 | 2014 | 433 | 0.390 |
Why?
|
| Neoplasms, Experimental | 1 | 2015 | 1298 | 0.370 |
Why?
|
| Craniotomy | 2 | 2011 | 730 | 0.350 |
Why?
|
| Supratentorial Neoplasms | 1 | 2010 | 162 | 0.340 |
Why?
|
| Oncolytic Viruses | 2 | 2023 | 318 | 0.340 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2011 | 359 | 0.340 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 2009 | 125 | 0.330 |
Why?
|
| Electromagnetic Fields | 1 | 2010 | 299 | 0.330 |
Why?
|
| Cancer Vaccines | 1 | 2015 | 1009 | 0.330 |
Why?
|
| Brachial Plexus Neuropathies | 1 | 2009 | 122 | 0.320 |
Why?
|
| Conscious Sedation | 1 | 2010 | 517 | 0.270 |
Why?
|
| Blood-Brain Barrier | 1 | 2011 | 986 | 0.270 |
Why?
|
| Fetal Diseases | 1 | 2010 | 884 | 0.260 |
Why?
|
| Neoplastic Stem Cells | 1 | 2013 | 1378 | 0.260 |
Why?
|
| Nanoparticles | 1 | 2015 | 1901 | 0.240 |
Why?
|
| Monitoring, Intraoperative | 1 | 2011 | 957 | 0.240 |
Why?
|
| Wakefulness | 1 | 2011 | 1231 | 0.240 |
Why?
|
| Central Nervous System | 1 | 2010 | 1301 | 0.230 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2011 | 857 | 0.230 |
Why?
|
| Anesthesia, General | 1 | 2010 | 1145 | 0.220 |
Why?
|
| Lymphoma, B-Cell | 1 | 2009 | 929 | 0.220 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2010 | 1662 | 0.220 |
Why?
|
| Nervous System Diseases | 2 | 2010 | 1620 | 0.210 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2011 | 2031 | 0.200 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2019 | 619 | 0.200 |
Why?
|
| Cell Movement | 2 | 2013 | 5287 | 0.190 |
Why?
|
| Herpesvirus 1, Human | 1 | 2023 | 749 | 0.160 |
Why?
|
| Gamma Rays | 1 | 2019 | 326 | 0.160 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2011 | 34776 | 0.140 |
Why?
|
| Genetic Vectors | 3 | 2019 | 3447 | 0.140 |
Why?
|
| Histone Demethylases | 1 | 2019 | 316 | 0.140 |
Why?
|
| Drug Delivery Systems | 2 | 2023 | 2230 | 0.130 |
Why?
|
| Humans | 26 | 2023 | 725187 | 0.120 |
Why?
|
| Cloning, Molecular | 1 | 2019 | 4388 | 0.120 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 1048 | 0.120 |
Why?
|
| Neuroglia | 1 | 2019 | 922 | 0.120 |
Why?
|
| Melanoma | 1 | 2011 | 5358 | 0.110 |
Why?
|
| Postoperative Complications | 2 | 2011 | 15019 | 0.110 |
Why?
|
| Mice, Nude | 1 | 2019 | 3713 | 0.110 |
Why?
|
| Signal Transduction | 2 | 2014 | 23448 | 0.110 |
Why?
|
| Cluster Analysis | 1 | 2019 | 2761 | 0.100 |
Why?
|
| Tumor Microenvironment | 3 | 2023 | 3335 | 0.100 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2019 | 3574 | 0.100 |
Why?
|
| Neurosurgical Procedures | 1 | 2021 | 1995 | 0.090 |
Why?
|
| Animals | 10 | 2021 | 168714 | 0.090 |
Why?
|
| Survival Analysis | 2 | 2023 | 10251 | 0.090 |
Why?
|
| Medical Oncology | 1 | 2021 | 2162 | 0.090 |
Why?
|
| Neurons | 1 | 2009 | 9344 | 0.090 |
Why?
|
| False Negative Reactions | 1 | 2010 | 588 | 0.090 |
Why?
|
| Anesthesia, Inhalation | 1 | 2010 | 221 | 0.090 |
Why?
|
| Exosomes | 1 | 2013 | 395 | 0.090 |
Why?
|
| Chromosomes, Artificial, Bacterial | 1 | 2009 | 128 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2009 | 192 | 0.090 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2010 | 317 | 0.080 |
Why?
|
| Clinical Trials as Topic | 3 | 2022 | 7840 | 0.080 |
Why?
|
| False Positive Reactions | 1 | 2010 | 991 | 0.080 |
Why?
|
| Etoposide | 1 | 2009 | 637 | 0.080 |
Why?
|
| Dacarbazine | 1 | 2010 | 567 | 0.080 |
Why?
|
| Vincristine | 1 | 2009 | 1050 | 0.080 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2010 | 795 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2009 | 698 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 1 | 2010 | 1533 | 0.070 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2009 | 639 | 0.070 |
Why?
|
| Epigenesis, Genetic | 1 | 2019 | 3596 | 0.070 |
Why?
|
| Prednisone | 1 | 2009 | 1549 | 0.060 |
Why?
|
| Cell Line, Tumor | 2 | 2019 | 16630 | 0.060 |
Why?
|
| Costs and Cost Analysis | 1 | 2010 | 1667 | 0.060 |
Why?
|
| Mice | 4 | 2019 | 80300 | 0.060 |
Why?
|
| Hydrocephalus | 1 | 2010 | 736 | 0.060 |
Why?
|
| Phenotype | 1 | 2021 | 16272 | 0.060 |
Why?
|
| Cyclophosphamide | 1 | 2009 | 2205 | 0.060 |
Why?
|
| Postoperative Care | 1 | 2010 | 1488 | 0.060 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 9379 | 0.060 |
Why?
|
| alpha-Synuclein | 1 | 2009 | 686 | 0.060 |
Why?
|
| Cell Proliferation | 1 | 2019 | 10477 | 0.060 |
Why?
|
| Doxorubicin | 1 | 2009 | 2226 | 0.060 |
Why?
|
| Methotrexate | 1 | 2009 | 1711 | 0.050 |
Why?
|
| Radiosurgery | 1 | 2011 | 1268 | 0.050 |
Why?
|
| Gestational Age | 1 | 2010 | 3443 | 0.050 |
Why?
|
| Female | 7 | 2019 | 375449 | 0.050 |
Why?
|
| Neoplasm Proteins | 1 | 2013 | 3711 | 0.050 |
Why?
|
| Neoplasm Metastasis | 1 | 2011 | 4896 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2018 | 8918 | 0.050 |
Why?
|
| Cerebral Hemorrhage | 1 | 2011 | 2576 | 0.050 |
Why?
|
| Neoplasms | 2 | 2021 | 20941 | 0.050 |
Why?
|
| Interleukin-12 | 1 | 2022 | 593 | 0.040 |
Why?
|
| tau Proteins | 1 | 2009 | 1750 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2023 | 19624 | 0.040 |
Why?
|
| Pathology, Molecular | 1 | 2022 | 336 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2010 | 38748 | 0.040 |
Why?
|
| Prognosis | 3 | 2019 | 28737 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2010 | 8617 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2023 | 61761 | 0.040 |
Why?
|
| Critical Care | 1 | 2010 | 2580 | 0.040 |
Why?
|
| Workflow | 1 | 2021 | 828 | 0.040 |
Why?
|
| Length of Stay | 1 | 2010 | 6234 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2022 | 74206 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2022 | 11324 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 14721 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 11484 | 0.030 |
Why?
|
| Adult | 4 | 2022 | 211615 | 0.030 |
Why?
|
| Prostheses and Implants | 1 | 2021 | 1362 | 0.030 |
Why?
|
| Microglia | 1 | 2022 | 1213 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2013 | 12080 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2009 | 19485 | 0.030 |
Why?
|
| Male | 4 | 2011 | 347096 | 0.030 |
Why?
|
| Rats | 1 | 2009 | 24414 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2009 | 9245 | 0.030 |
Why?
|
| Spheroids, Cellular | 1 | 2013 | 341 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2022 | 3643 | 0.020 |
Why?
|
| Biological Transport | 1 | 2013 | 2117 | 0.020 |
Why?
|
| Pregnancy | 1 | 2010 | 28145 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2010 | 39918 | 0.020 |
Why?
|
| Aged | 2 | 2010 | 161486 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2022 | 4257 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2009 | 13576 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2023 | 10007 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2013 | 6371 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2014 | 1719 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2013 | 3628 | 0.020 |
Why?
|
| Simplexvirus | 1 | 2009 | 803 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2013 | 2650 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 2009 | 1450 | 0.010 |
Why?
|
| Adolescent | 1 | 2011 | 84401 | 0.010 |
Why?
|
| Gene Expression | 1 | 2013 | 7819 | 0.010 |
Why?
|
| Mutation | 1 | 2022 | 29672 | 0.010 |
Why?
|
| Middle Aged | 1 | 2010 | 212292 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2013 | 18033 | 0.010 |
Why?
|